Gilead Sciences | GILD - Net Income


Gilead Sciences reported $-10.5B in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
AbbVie USD 3.61B 2.92B Jun/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
ALKERMES USD 501K 66.98M Jun/2026
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
Amgen USD 2.38B 556M Jun/2026
Biogen USD 97.5M 222M Jun/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Eli Lilly USD 7.1B 301M Jun/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 435M 1.3B Jun/2026
Glaxosmithkline GBP 1.74B 890.94M Mar/2026
Incyte USD 585.6M 282.27M Jun/2026
J&J USD 5.53B 299M Jun/2026
Merck USD -1.34B 2.9B Jun/2026
Moderna USD -1.34B 517M Mar/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
Novartis USD 3.26B 108M Jun/2026
Pfizer USD -248M 2.94B Jun/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR 343M 1.27B Jun/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
United Therapeutics USD 333M 58.1M Jun/2026
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026